Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Foeniculum vulgare seed extract (FVE), commonly known as fennel seed extract, is a botanical preparation being investigated for its anti-cancer properties, specifically against hepatocellular carcinoma (HCC). Research indicates that ethanol extracts of these seeds reduce cell viability, inhibit cell migration, and induce apoptosis in malignant cells. The mechanism of action involves the down-regulation of the oncoprotein survivin (BIRC5), which triggers mitochondrial toxicity and leads to the activation of caspase-3. In vivo studies using HCC xenograft models in nude mice have shown that the extract significantly inhibits tumor growth while exhibiting minimal toxicity to normal liver cells. This selective apoptotic effect suggests potential for the extract as a targeted therapeutic agent in oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on foeniculum vulgare seed extract.